Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals.
Clelia ChalumeauMatthieu CartonAlexandre EeckhoutteStelly BalletAnne-Vincent SalomonPerrine VuagnatAudrey BellesoeurJean-Yves PiergaMarc-Henri SternFrancois-Clement BidardFlorence LereboursPublished in: Cancers (2022)
Our analysis suggests a favorable efficacy and toxicity profile for VP16-T in patients with heavily pretreated HER2+ MBC.